title: Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late.
abstract: Plerixafor can rescue the outcome of failing chemotherapy-based stem cell mobilization. However, the optimal time for plerixafor injection in this setting has not been determined. This was investigated by retrospective analysis of data from 48 mobilizations with plerixafor, chemotherapy, and granulocyte-colony stimulating factor (G-CSF). The required yield of 2.0 × 10(6) CD34+ cells/kg was collected from 71% of patients; the median total yield was 4.1 × 10(6) CD34+ cells/kg. Patients to whom plerixafor was administered late (≥ 15 days) after chemotherapy, after a long duration (≥ 13 days) of treatment with G-CSF, or when the white blood cell count was high (≥ 20 × 10(9)/L) were mobilized as efficiently as other patients. Plerixafor was shown to rescue mobilizations at a comparable rate in patients with critically low levels of peripheral blood CD34+ cells (<3/µL) and those with higher concentrations. These data suggest that late administration of plerixafor in the course of chemotherapy-based mobilization does not contribute to the failure of this strategy.
authors.affiliation: Department of Hematology, Oncology and Internal Diseases, The Medical University of Warsaw, Warsaw, Argentina. gbasak@ib.amwaw.edu.pl
authors.forename: Grzegorz W
authors.initials: GW
authors.lastname: Basak
authors.forename: Gabor
authors.initials: G
authors.lastname: Mikala
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Koristek
authors.forename: Ozren
authors.initials: O
authors.lastname: Jaksic
authors.forename: Sandra
authors.initials: S
authors.lastname: Basic-Kinda
authors.forename: Andrea
authors.initials: A
authors.lastname: Cegledi
authors.forename: Marienn
authors.initials: M
authors.lastname: Reti
authors.forename: Tamas
authors.initials: T
authors.lastname: Masszi
authors.forename: Jiri
authors.initials: J
authors.lastname: Mayer
authors.forename: Sebastian
authors.initials: S
authors.lastname: Giebel
authors.forename: Kai
authors.initials: K
authors.lastname: Hübel
authors.forename: Boris
authors.initials: B
authors.lastname: Labar
authors.forename: Wieslaw
authors.initials: W
authors.lastname: Wiktor-Jedrzejczak
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001596:Benzylamines; D000080027:Cyclams; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells / Q000187:drug effects / Q000378:metabolism; D006571:Heterocyclic Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018952:Antigens, CD34; D000970:Antineoplastic Agents; D001596:Benzylamines; D000080027:Cyclams; D006571:Heterocyclic Compounds; D016179:Granulocyte Colony-Stimulating Factor; C088327:plerixafor